ACLY and hepatocellular carcinoma: Cinobufotalin can also selectively block the interaction of sterol regulatory element-binding protein 1 (SREBP1) with sterol regulatory elements (SRE) in HepG2, LM3, and SMMC7721 cells, reducing the transcriptional activity of SREBP1, thereby inhibiting the expression of fat generation-related genes acetyl-CoA carboxylase (ACC), ATP citrate lyase (ACLY), fatty acid synthase (FASN), Stearoyl-CoA desaturase-1 (SCD1), and treating HCC by inhibiting de novo fat synthesis (Meng et al., 2021).